INTEGRATION OF ‘TOTAL MANAGEMENT’ STRUCTURE AND EXPANSION OF ITS DRUG PORTFOLIO ARE A MUST FOR PFIZER
Where the
world worships heroes on one hand, it also criticises them most strongly when they stumble. Look at the $180 billion worth Pfizer – the world’s largest drug manufacturer whose latest attempt to repeat its previous incredible feat of manufacturing the world’s highest-selling drug (when it acquired Lipitor from Warner- Lambert in 1996) failed, thus casting a thick cloud of worry over the management. Following high count of patient deaths during drug-tests of its much hyped Torcetrapib, it finally dropped the drug on December 2, 2006, bringing a question to the surface – ‘What will happen post-expiry of its $12.9 billion revenue-earning Lipitor (amounting to 25% of total annual revenues in 2005) in 2011?’
For Complete IIPM Article, Click on IIPM Article
Where the
world worships heroes on one hand, it also criticises them most strongly when they stumble. Look at the $180 billion worth Pfizer – the world’s largest drug manufacturer whose latest attempt to repeat its previous incredible feat of manufacturing the world’s highest-selling drug (when it acquired Lipitor from Warner- Lambert in 1996) failed, thus casting a thick cloud of worry over the management. Following high count of patient deaths during drug-tests of its much hyped Torcetrapib, it finally dropped the drug on December 2, 2006, bringing a question to the surface – ‘What will happen post-expiry of its $12.9 billion revenue-earning Lipitor (amounting to 25% of total annual revenues in 2005) in 2011?’For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2006
An IIPM and Management Guru Professor Arindam Chaudhuri's Initiative
No comments:
Post a Comment